| Condition or disease | Intervention/treatment |
|---|---|
| Trauma Injuries | Diagnostic Test: Blood samples for DNA methylation analysis |
Background: Severe trauma is an extreme physical exposure, which may have significant consequences for the patient. In addition to anatomical injury and hemodynamic compromise, severe trauma causes an immense and rapid systemic immune reaction. At the genomic level, trauma has been found to significantly increase gene expression in circulating leukocytes, and preliminary data is also emerging that trauma may even cause epigenetic (DNA methylation) alterations.
Epigenetics, including DNA methylation, have been suggested as a mediator of genetic risk and to play a significant role in subsequent non-traumatic disease. Within the field of trauma DNA methylation has only been sparsely studied, but a few studies of traumatized animals have suggested that DNA methylation alterations may occur in relation to trauma. Even though DNA methylation is highly dynamic, some marks have been found to be stable over time, and thus may have long-term consequences.
An increasing understanding of the role of epigenetics in disease development and response may pave the way for new treatment targets and modalities for multiple diseases including trauma.
Research question: Does trauma induce immediate (<4 hours) and persistent (30 days post-trauma) changes in the epigenome of peripheral blood cells, and do epigenetic changes correlate with patient recovery?
Objectives: To identify potential early alterations in the DNA methylation profile after severe trauma AND to investigate if the early marks persist.
Study design: A prospective, observational, cohort study of trauma patients admitted to RH's trauma center. The trauma cohort will be compared to a cohort of patients admitted for elective orthopedic surgery in terms of DNA methylation profile in blood cells pre-trauma/surgery, immediately post-trauma/surgery, and 30-45 days post-trauma/surgery.
DNA methylation profiles will be assessed by array technique using Illumina's MethylationEPIC Bead-Chip.
Primary outcome: Immediate (<4 hours) post-trauma DNA methylation profile in blood cells.
Secondary outcomes: Pre-trauma/surgery DNA methylation profile, change in DNA methylation from pre-trauma/surgery to immediately and 30 days post-trauma/surgery, occurrence of organ dysfunction, sepsis, septic shock, 30-day mortality, ICU admission > 24 hours, ICU length of stay (LOS), hospital LOS.
| Study Type : | Observational |
| Actual Enrollment : | 365 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Identification of the Epigenetic Response to Trauma - a Prospective, Observational Study |
| Actual Study Start Date : | June 3, 2019 |
| Actual Primary Completion Date : | April 15, 2021 |
| Estimated Study Completion Date : | December 31, 2021 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Trauma patients
All trauma patients admitted to Rigshospitalet's trauma center will have a blood sample taken during the initial treatment and 30 days after the trauma.
|
Diagnostic Test: Blood samples for DNA methylation analysis
DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
|
|
Patients admitted for elective orthopedic surgery
The patients will have a blood sample taken before and after surgery and again 30 days after the surgery.
|
Diagnostic Test: Blood samples for DNA methylation analysis
DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
|
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
The study population consists of all trauma patients admitted to RH's trauma center generating a trauma team activation.
The control group will consist of patients admitted to RH's orthopedic department for elective surgery.
Inclusion Criteria:
Surgical controls: Admitted for elective surgery (non-traumatic cause) at the orthopedics department AND
Exclusion Criteria:
Trauma patients:
Surgical controls:
| Denmark | |
| Rigshospitalet | |
| Copenhagen, Denmark, 2100 | |
| Study Director: | Jacob Steinmetz, MD, Ph.D. | Rigshospitalet, Denmark |
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date | May 29, 2019 | ||||
| First Posted Date | June 4, 2019 | ||||
| Last Update Posted Date | May 7, 2021 | ||||
| Actual Study Start Date | June 3, 2019 | ||||
| Actual Primary Completion Date | April 15, 2021 (Final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures |
Immediate DNA methylation profile [ Time Frame: Day of trauma/surgery ] Immediate (< 4 hours) post-trauma DNA methylation profile in blood cells compared to the pre-surgery (baseline) and immediate post-surgery (< 4 hours) DNA methylation profile in blood cells.
|
||||
| Original Primary Outcome Measures | Same as current | ||||
| Change History | |||||
| Current Secondary Outcome Measures |
|
||||
| Original Secondary Outcome Measures | Same as current | ||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title | Identification of the Epigenetic Response to Trauma | ||||
| Official Title | Identification of the Epigenetic Response to Trauma - a Prospective, Observational Study | ||||
| Brief Summary | The objective of this study is to investigate potential early alterations in the DNA methylation profile after severe trauma and to investigate if the early marks persist. | ||||
| Detailed Description |
Background: Severe trauma is an extreme physical exposure, which may have significant consequences for the patient. In addition to anatomical injury and hemodynamic compromise, severe trauma causes an immense and rapid systemic immune reaction. At the genomic level, trauma has been found to significantly increase gene expression in circulating leukocytes, and preliminary data is also emerging that trauma may even cause epigenetic (DNA methylation) alterations. Epigenetics, including DNA methylation, have been suggested as a mediator of genetic risk and to play a significant role in subsequent non-traumatic disease. Within the field of trauma DNA methylation has only been sparsely studied, but a few studies of traumatized animals have suggested that DNA methylation alterations may occur in relation to trauma. Even though DNA methylation is highly dynamic, some marks have been found to be stable over time, and thus may have long-term consequences. An increasing understanding of the role of epigenetics in disease development and response may pave the way for new treatment targets and modalities for multiple diseases including trauma. Research question: Does trauma induce immediate (<4 hours) and persistent (30 days post-trauma) changes in the epigenome of peripheral blood cells, and do epigenetic changes correlate with patient recovery? Objectives: To identify potential early alterations in the DNA methylation profile after severe trauma AND to investigate if the early marks persist. Study design: A prospective, observational, cohort study of trauma patients admitted to RH's trauma center. The trauma cohort will be compared to a cohort of patients admitted for elective orthopedic surgery in terms of DNA methylation profile in blood cells pre-trauma/surgery, immediately post-trauma/surgery, and 30-45 days post-trauma/surgery. DNA methylation profiles will be assessed by array technique using Illumina's MethylationEPIC Bead-Chip. Primary outcome: Immediate (<4 hours) post-trauma DNA methylation profile in blood cells. Secondary outcomes: Pre-trauma/surgery DNA methylation profile, change in DNA methylation from pre-trauma/surgery to immediately and 30 days post-trauma/surgery, occurrence of organ dysfunction, sepsis, septic shock, 30-day mortality, ICU admission > 24 hours, ICU length of stay (LOS), hospital LOS. |
||||
| Study Type | Observational | ||||
| Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Retention: Samples With DNA Description:
Blood samples are obtained from patients to investigate DNA methylation profiles
|
||||
| Sampling Method | Probability Sample | ||||
| Study Population |
The study population consists of all trauma patients admitted to RH's trauma center generating a trauma team activation. The control group will consist of patients admitted to RH's orthopedic department for elective surgery. |
||||
| Condition |
|
||||
| Intervention | Diagnostic Test: Blood samples for DNA methylation analysis
DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
|
||||
| Study Groups/Cohorts |
|
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status | Active, not recruiting | ||||
| Actual Enrollment |
365 | ||||
| Original Estimated Enrollment |
360 | ||||
| Estimated Study Completion Date | December 31, 2021 | ||||
| Actual Primary Completion Date | April 15, 2021 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria:
|
||||
| Sex/Gender |
|
||||
| Ages | 18 Years to 65 Years (Adult, Older Adult) | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries | Denmark | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT03974048 | ||||
| Other Study ID Numbers | VD-2019-161 | ||||
| Has Data Monitoring Committee | No | ||||
| U.S. FDA-regulated Product |
|
||||
| IPD Sharing Statement |
|
||||
| Responsible Party | Trine Grodum Eskesen, Rigshospitalet, Denmark | ||||
| Study Sponsor | Rigshospitalet, Denmark | ||||
| Collaborators | Not Provided | ||||
| Investigators |
|
||||
| PRS Account | Rigshospitalet, Denmark | ||||
| Verification Date | May 2021 | ||||